Edoxaban
Cardiovascular - AF
Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: Results from the noninterventional Global ETNA-AF programme
Morrone D, Dinshaw L, de Souza JAG, et al.
Eur Heart J Open. 2025 Mar;5(2):oeaf004. doi: 10.1093/ehjopen/oeaf004.
T-DXd
Breast Cancer
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low breast cancer in Taiwan
Lee K-T, Huang P-H, Hsu C-Y, et al.
Cancer Treat Res Commun. 2025 Mar;43:100893. doi: 10.1016/j.ctarc.2025.100893.
Quizartinib
Hematology
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial
Schlenk RF, Montesinos P, Kim H-J, , et al.
Haematologica. 2025 Mar. doi: 10.3324/haematol.2024.286623.
Dato-DXd
Breast Cancer
Lung Cancer
Other/Multi
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
Meric-Bernstam F, Bardia A, Bossi P, et al.
Oncologist. 2025 Mar;30(3):oyaf031. doi: 10.1093/oncolo/oyaf031.
Dato-DXd
Lung Cancer
Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study
Ahn M-J, Tanaka K, Paz-Ares L, et al.
J Clin Oncol. 2025;43(3):260-272. doi: 10.1200/JCO-24-01544.
T-DXd
Breast Cancer
TUXEDO-4: Phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
Marhold M, Vaz Batista M, Blancas I, et al.
Future Oncol. 2025 Apr;21(9):1065-1073. doi: 10.1080/14796694.2025.2470604.
Edoxaban
Cardiovascular - AF
Two‐year follow‐up of patients with atrial fibrillation receiving edoxaban in routine clinical practice: Results from the global ETNA‐AF program
De Caterina R, Unverdorben M, Chen C, et al.
Clin Cardiol. 2025 Feb;48(3):e70091. doi: 10.1002/clc.70091.
T-DXd
Lung Cancer
Analytical and clinical validation of the plasma-based Guardant360 CDx test for assessing HER2 (ERBB2) mutation status in patients with non-small-cell lung cancer for treatment with trastuzumab deruxtecan in DESTINY-Lung01/02
Qi Z, Tokuhiro S, Odegaard JI, et al.
J Mol Diagn. 2025;27(2):119-129.
T-DXd
Breast Cancer
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
Dennis N, Dunton K, Livings C,et al.
Eur J Cancer. 2024;217:115192. doi: 10.1016/j.ejca.2024.115192
T-DXd
Breast Cancer
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
Dennis N, Dunton K, Livings C, et al.
Eur J Cancer. 2025 Feb;217:115192. doi: 10.1016/j.ejca.2024.115192.
